Project Grant W81XWH2210385

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...

This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...

This $675,107 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is supporting research conducted by Northeastern University to develop novel, non-opioid, and non-addictive analgesics for treating neuropathic pain. The primary objectives are to design and synthesize a series of new "dualsteric modulators" that act as both non-psychoactive...

This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $23,579,701 in funding to Ensysce Biosciences, Inc. from September 1, 2024 to May 31, 2027 to continue the clinical development of PF614-MPAR. PF614-MPAR is a novel opioid product that combines a trypsin-activated abuse protection (TAAP) technology with a trypsin inhibitor to provide overdose protection. The goals of this project are to...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $591,842 to Rebel Medicine Inc., a biotechnology company in Salt Lake City, Utah, to develop an extended-duration, injectable local anesthetic formulation that can reduce the need for opioid medications after surgery. The project aims to demonstrate the safety and efficacy of a proprietary oleogel-based delivery system that can provide up...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...

This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into a novel, non-opioid spinal analgesic mechanism for the treatment of high-impact chronic pain. The $664,772 award to the University of Texas Southwestern Medical Center aims to dissect the signaling pathway involving the neurotensin receptor 2 (NTSR2)...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $387,000 to Florida Atlantic University (FAU) to develop novel cyclic peptide analgesics for intranasal delivery as an alternative to existing pain medications. The key objectives are to: (1) further improve the analgesic properties and minimize side effects of cyclic peptides based on odorranalectin, (2) assess the metabolic stability...

This Project Grant award of $598,312 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the integration and assessment of Addinex Technologies, Inc.'s closed-loop medication management system for opioid pain management in ambulatory patients with extremity fractures being discharged from the emergency department. The primary objectives are to: 1) adapt and enhance the Addinex system to align with hospital pharmacy...